pH-Responsive Nanostructures Based on Surface Active Fatty Acid-Protic Ionic Liquids for Imiquimod Delivery in Skin Cancer Topical Therapy.
imiquimod
ionic liquids
nanostructures
skin cancer
topical drug delivery
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
11 Nov 2020
11 Nov 2020
Historique:
received:
30
09
2020
revised:
06
11
2020
accepted:
07
11
2020
entrez:
14
11
2020
pubmed:
15
11
2020
medline:
15
11
2020
Statut:
epublish
Résumé
For topical treatment of skin cancer, the design of pH-responsive nanocarriers able to selectively release the drug in the tumor acidic microenvironment represents a reliable option for targeted delivery. In this context, a series of newly synthesized surface-active fatty acid-protic ionic liquids (FA-PILs), based on tetramethylguanidinium cation and different natural hydrophobic fatty acid carboxylates, have been investigated with the aim of developing a pH-sensitive nanostructured drug delivery system for cutaneous administration in the skin cancer therapy. The capability of FA-PILs to arrange in micelles when combined with each other and with the non-ionic surfactant d-α-Tocopherol polyethylene glycol succinate (vitamin E TPGS) as well as their ability to solubilize imiquimod, an immuno-stimulant drug used for the treatment of skin cancerous lesions, have been demonstrated. The FA-PILs-TPGS mixed micelles showed pH-sensitivity, suggesting that the acidic environment of cancer cells can trigger nanostructures' swelling and collapse with consequent rapid release of imiquimod and drug cytotoxic potential enhancement. The in vitro permeation/penetration study showed that the micellar formulation produced effective imiquimod concentrations into the skin exposed to acid environment, representing a potential efficacious and selective drug delivery system able to trigger the drug release in the tumor tissues, at lower and less irritating drug concentrations.
Identifiants
pubmed: 33187215
pii: pharmaceutics12111078
doi: 10.3390/pharmaceutics12111078
pmc: PMC7697672
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Università di Pisa
ID : PRA_2018_18
Références
J Invest Dermatol. 2014 Oct;134(10):2551-2561
pubmed: 24751730
Int J Cosmet Sci. 2015 Jun;37(3):298-305
pubmed: 25565399
J Control Release. 2016 Aug 10;235:182-194
pubmed: 27264552
Chem Rev. 2015 Oct 28;115(20):11379-448
pubmed: 26426209
Expert Rev Anticancer Ther. 2010 Nov;10(11):1797-809
pubmed: 21080805
Eur J Pharm Biopharm. 2019 Sep;142:553-562
pubmed: 30641138
J R Soc Interface. 2012 Mar 7;9(68):487-502
pubmed: 21865255
Phys Chem Chem Phys. 2017 May 3;19(17):10835-10842
pubmed: 28387400
Eur J Pharm Sci. 2015 Sep 18;77:279-89
pubmed: 26091570
Mol Pharm. 2015 Jun 1;12(6):1980-91
pubmed: 25905624
Magn Reson Med. 2014 Jan;71(1):326-32
pubmed: 23529973
Anticancer Res. 2017 Nov;37(11):5941-5953
pubmed: 29061773
J AOAC Int. 2018 Mar 1;101(2):437-443
pubmed: 28766480
Chemphyschem. 2017 Oct 6;18(19):2560-2572
pubmed: 28719104
ChemMedChem. 2019 Oct 17;14(20):1767-1770
pubmed: 31603287
Int J Biol Macromol. 2019 May 1;128:740-751
pubmed: 30699336
Adv Mater. 2020 May;32(18):e1904205
pubmed: 31957144
Life Sci. 2017 Apr 1;174:50-58
pubmed: 28238718
Molecules. 2019 May 09;24(9):
pubmed: 31075867
Toxicol Lett. 2018 May 15;288:82-88
pubmed: 29410238
Pharmaceutics. 2020 Mar 11;12(3):
pubmed: 32168973
J Control Release. 2016 Nov 28;242:3-15
pubmed: 27449743
Nanomaterials (Basel). 2019 Oct 13;9(10):
pubmed: 31614947
Molecules. 2020 Aug 11;25(16):
pubmed: 32796649
Dermatol Clin. 2005 Jan;23(1):151-64, vii
pubmed: 15620626
Pharmaceutics. 2020 Mar 24;12(3):
pubmed: 32213930
Mol Pharm. 2017 Oct 2;14(10):3281-3289
pubmed: 28825487
Pharmaceutics. 2019 Mar 20;11(3):
pubmed: 30897794
Am J Clin Dermatol. 2004;5(6):453-8
pubmed: 15663342
Int J Pharm. 2014 Jul 20;469(1):179-89
pubmed: 24746413
Theranostics. 2018 Jan 1;8(2):464-485
pubmed: 29290821
Front Pharmacol. 2020 Sep 23;11:574317
pubmed: 33071785
Prog Biomater. 2017 May;6(1-2):13-26
pubmed: 28303522
Langmuir. 2007 Apr 10;23(8):4178-82
pubmed: 17346069
Chem Rev. 2017 May 24;117(10):7132-7189
pubmed: 28125212
Biomed Res Int. 2014;2014:895986
pubmed: 25101298
Skin Pharmacol Physiol. 2018;31(2):59-73
pubmed: 29262420
Phys Chem Chem Phys. 2017 Mar 22;19(12):8201-8209
pubmed: 28263333
Int J Pharm. 2018 Jan 15;535(1-2):253-260
pubmed: 29113804
J Dermatol Sci. 2015 Nov;80(2):124-32
pubmed: 26360010
Cancers (Basel). 2015 Jul 01;7(3):1154-77
pubmed: 26140669
J Am Acad Dermatol. 2014 Jun;70(6):965.e1-12; quiz 977-8
pubmed: 24831324
PLoS One. 2017 Aug 10;12(8):e0182022
pubmed: 28797090
Exp Biol Med (Maywood). 2008 Aug;233(8):968-79
pubmed: 18480416
Colloids Surf B Biointerfaces. 2019 Feb 1;174:232-245
pubmed: 30465998
J Colloid Interface Sci. 2019 Sep 1;551:72-80
pubmed: 31075635
Molecules. 2018 Dec 20;24(1):
pubmed: 30577475
Dermatology. 2002;205(2):135-8
pubmed: 12218228
Sci Rep. 2017 Apr 21;7:46673
pubmed: 28429753
Acta Biomater. 2019 Dec;100:142-157
pubmed: 31586728
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818791795
pubmed: 30099929
Int J Pharm. 2016 Apr 30;503(1-2):1-7
pubmed: 26930566
Drug Deliv Transl Res. 2018 Jun;8(3):461-472
pubmed: 29633172
J Pharm Sci. 2018 Jan;107(1):203-216
pubmed: 28549907
Drug Deliv Transl Res. 2020 Dec;10(6):1829-1840
pubmed: 32562254
Chem Commun (Camb). 2015 Aug 28;51(67):13170-3
pubmed: 26165252
Eur J Pharm Biopharm. 2019 Mar;136:9-17
pubmed: 30630060